UNSPSC 51401556: Tolufazepam

This classification denotes a benzodiazepine with the molecular formula C24H20Cl2N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98SR74X50D, chemically known as 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-1-(2-(p-tolylsulfonyl)ethyl)-2h-1,4-benzodiazepin-2-one but generally known as tolufazepam, which bears US NIH Compound Identifier 65647. European Medicines Agency schedules Tolufazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11182MIG.

UNSPSC 51401556 Tolufazepam is a Commodity code that nominally describes a specific pharmaceutical product, but recent state and local procurement activity under this code shows little alignment with that narrow definition. Instead, issuing bodies are soliciting pharmaceutical supply agreements, drug-deactivation systems, and pharmacy benefit programs across a broader scope. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and Seminole County, Florida have posted competitive opportunities for generic pharmaceuticals and over-the-counter products, naloxone, and drug-deactivation systems through RFP and IFB processes. The Texas Health and Human Services Commission has issued a Request for Information to explore direct-to-manufacturer prescription programs. Issuing bodies span state health and human services departments, county health systems, and cooperative purchasing organizations that aggregate demand across multiple state and local jurisdictions. The code shows minimal direct activity specific to tolufazepam itself and appears to be used as a catch-all for broader pharmaceutical procurement rather than the specific benzodiazepine the code nominally describes.

Recent activity concentrates in the South and Upper Midwest. The MMCAP RFP, administered by the Minnesota Department of Administration, covers participating state and local facilities across Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness targeted for July 1, 2026. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug-deactivation systems annually with a response deadline of July 26, 2026, and quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs without a formal competitive timeline. The code's activity reflects state and local interest in pharmaceutical supply chain efficiency, cost management through cooperative purchasing, and community health interventions such as naloxone distribution, but the code itself does not align clearly with the work being solicited.